Subscribe To
AGIO / Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript
![Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/r/j/transcript18-2005032.jpg)
Content Topics
Agios
Pharmaceuticals
Inc
AGIO
2023
Earnings
Call
Pharmaceuticals
agio
Transcript
Stock
AGIO News
![Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales](https://cdn.snapi.dev/images/v1/0/c/594-2139573.jpg)
By Zacks Investment Research
November 3, 2023
Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales
Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same. more_horizontal
![Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition](https://cdn.snapi.dev/images/v1/3/a/conf4-2136189.jpg)
By GlobeNewsWire
November 2, 2023
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease more_horizontal
![Agios Pharmaceuticals: Positive Phase 2 Results In Sickle Cell Study Agios Pharmaceuticals: Positive Phase 2 Results In Sickle Cell Study](https://cdn.snapi.dev/images/v1/6/f/image-1421515036-2026518.jpg)
By Seeking Alpha
August 17, 2023
Agios Pharmaceuticals: Positive Phase 2 Results In Sickle Cell Study
Agios Pharmaceuticals is a biotech company focused on developing medicines for cancer and rare genetic diseases. The company's financials show growth, more_horizontal
![Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line](https://cdn.snapi.dev/images/v1/5/e/382-2007530.jpg)
By Zacks Investment Research
August 4, 2023
Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line
Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate. more_horizontal
![Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/r/j/transcript18-2005032.jpg)
By Seeking Alpha
August 3, 2023
Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2023 Results Conference Call August 3, 2023 8:00 AM ET Company Participants Christopher Taylor - Vice Pr more_horizontal
![Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet](https://cdn.snapi.dev/images/v1/8/r/default32-1974207.jpg)
By Zacks Investment Research
July 17, 2023
Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Agios Pharmaceuticals (AGIO). While the effectivenes more_horizontal
![Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year? Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?](https://cdn.snapi.dev/images/v1/e/3/default12-1951798.jpg)
By Zacks Investment Research
June 28, 2023
Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?
Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year. more_horizontal
![Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint](https://cdn.snapi.dev/images/v1/v/p/3899-1950296.jpg)
By Zacks Investment Research
June 27, 2023
Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint
Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed wi more_horizontal